Zilucoplan
Also referenced as: Zilbrysq
A macrocyclic peptide inhibitor of complement C5 used for a defined myasthenia-gravis population.
- Evidence grade
- AStrong Clinical Evidence
Strong Clinical Evidence
- Regulatory status
- FDA Approved for Specific Indication
Zilbrysq is FDA-approved for generalized myasthenia gravis in anti-AChR-antibody-positive adults.
- Human data
- Yes
Registered clinical trials exist
- Last reviewed
- October 27, 2026
Overview
A macrocyclic peptide inhibitor of complement C5 used for a defined myasthenia-gravis population.
Zilbrysq is FDA-approved for generalized myasthenia gravis in anti-AChR-antibody-positive adults.
REMS and infection precautions are part of care; this is not a muscle-growth or recovery peptide.
Why It's Being Studied
- Generalized myasthenia gravis
- Complement inhibition
Mechanism of Action
C5 inhibition blocks terminal complement activity implicated in neuromuscular injury.
C5 inhibition blocks terminal complement activity implicated in neuromuscular injury. REMS and infection precautions are part of care; this is not a muscle-growth or recovery peptide.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- Generalized myasthenia gravis
- Complement inhibition
- Subcutaneous approved medicine
Evidence Summary
Phase 3 RAISE supports symptom improvements in anti-AChR-positive adult generalized myasthenia gravis.
Higher tiers carry more weight. Filled tiers have evidence for Zilucoplan; tap to read it.
- Phase 3 RAISE supports symptom improvements in anti-AChR-positive adult generalized myasthenia gravis.
1 cited sources.
- Prescribing label1
Human clinical evidence
- Phase 3 RAISE supports symptom improvements in anti-AChR-positive adult generalized myasthenia gravis.
Reported Adverse Events in Research
- A boxed warning covers life-threatening meningococcal infection; vaccination does not eliminate risk. Pancreatic adverse effects are also important.
Limitations of Current Evidence
- REMS and infection precautions are part of care; this is not a muscle-growth or recovery peptide.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| Zilucoplan | Trofinetide | |
|---|---|---|
| Evidence grade | A — Strong Clinical Evidence | B — Moderate Human Evidence |
| Regulatory status | FDA Approved for Specific Indication | FDA Approved for Specific Indication |
| Human data | Yes | Yes |
| Clinical trials | Registered trials exist | Registered trials exist |
| Research routes | Subcutaneous approved medicine | Oral approved medicine |
| Cited sources | 1 | 2 |
Frequently Asked Questions
Research References
- Prescribing label
Zilucoplan — prescribing label